Science & Enterprise subscription

Follow us on Twitter

  • An easy-to-use device for measuring intraocular pressure responsible for glaucoma is in development by University o… https://t.co/XNVgZXtsw9
    about 21 mins ago
  • New post on Science and Enterprise: Home Eye Pressure Gauge in the Works https://t.co/5OETI9igDD #Science #Business
    about 23 mins ago
  • A biotechnology company is sponsoring university research on light waves reacting in characteristic patterns for de… https://t.co/RG11kdD0as
    about 19 hours ago
  • New post on Science and Enterprise: Univ Lab, Company Developing Phone-Based Virus Sensor https://t.co/Yqq5wZPmqF #Science #Business
    about 19 hours ago
  • A blood test designed for low-resource field settings is shown to quickly detect and distinguish between different… https://t.co/7RCwijmW7N
    about 1 day ago

Please share Science & Enterprise

Covid-19 Vaccines, Therapies – 10 August 2020

Covid-19 vaccine and therapy tracker

BioRender Covid-19 vaccine and therapy tracker. (BioRender.com)

10 Aug. 2020.  A regular Monday feature on Science & Enterprise is an update on Covid-19 therapies and vaccines in development. The report is provided by BioRender, in Toronto, Ontario, a company offering illustration and graphics tools for life sciences, biotechnology, and other disciplines.

This week’s chart shows a burst of activity for both Covid-19 vaccines and therapies since last Monday. Seven new vaccine projects got underway last week, raising the total to 164, with six more vaccines reaching clinical trials now totaling 41. And 19 more therapies are in development, bringing that total to 356, while 11 more therapies entered clinical trials, raising that total to 270.

In addition to the summary dashboard shown above, the BioRender Covid-19 vaccine and therapy page provides details of the vaccines and therapies, as well as an activity feed showing news updates on these drugs.

The race to develop both vaccines and therapies for Covid-19 has put a spotlight on adaptive clinical trials, a new type of study that produces quality data like gold-standard randomized clinical trials, but allows for more complex conditions, altering course in the middle of the trial, and testing multiple drugs or medical devices at one time. Last week, as reported by Science & Enterprise, National Institutes of Health launched its Activ-2 and Activ-3 clinical trials, mid- and late-stage studies of Covid-19 therapies using an adaptive design.

More from Science & Enterprise:

*     *     *

2 comments to Covid-19 Vaccines, Therapies – 10 August 2020